Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260

1.

Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer.

Pietrowska M, Marczak L, Polanska J, Behrendt K, Nowicka E, Walaszczyk A, Chmura A, Deja R, Stobiecki M, Polanski A, Tarnawski R, Widlak P.

J Transl Med. 2009 Jul 13;7:60. doi: 10.1186/1479-5876-7-60.

2.

Optimizing of MALDI-ToF-based low-molecular-weight serum proteome pattern analysis in detection of breast cancer patients; the effect of albumin removal on classification performance.

Pietrowska M, Marczak L, Polanska J, Nowicka E, Behrent K, Tarnawski R, Stobiecki M, Polanski A, Widlak P.

Neoplasma. 2010;57(6):537-44.

PMID:
20845992
3.

Mass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early-stage breast cancer.

Pietrowska M, Polanska J, Marczak L, Behrendt K, Nowicka E, Stobiecki M, Polanski A, Tarnawski R, Widlak P.

J Transl Med. 2010 Jul 11;8:66. doi: 10.1186/1479-5876-8-66.

4.

Proteomic Profiling of Invasive Ductal Carcinoma (IDC) using Magnetic Beads-based Serum Fractionation and MALDI-TOF MS.

Yang J, Zhu J, He K, Zhao LY, Liu LY, Song TS, Huang C.

J Clin Lab Anal. 2015 Jul;29(4):321-7. doi: 10.1002/jcla.21773. Epub 2014 Aug 17.

PMID:
25130542
5.

Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: association with tumor progression.

Pietrowska M, Polańska J, Suwiński R, Wideł M, Rutkowski T, Marczyk M, Domińczyk I, Ponge L, Marczak L, Polański A, Widłak P.

Int J Oncol. 2012 Jan;40(1):148-56. doi: 10.3892/ijo.2011.1186. Epub 2011 Sep 5.

PMID:
21894432
6.

Identification of serum proteome signatures of locally advanced and metastatic gastric cancer: a pilot study.

Abramowicz A, Wojakowska A, Gdowicz-Klosok A, Polanska J, Rodziewicz P, Polanowski P, Namysl-Kaletka A, Pietrowska M, Wydmanski J, Widlak P.

J Transl Med. 2015 Sep 17;13:304. doi: 10.1186/s12967-015-0668-9.

7.

Potential biomarkers for esophageal carcinoma detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Liu LH, Shan BE, Tian ZQ, Sang MX, Ai J, Zhang ZF, Meng J, Zhu H, Wang SJ.

Clin Chem Lab Med. 2010 Jun;48(6):855-61. doi: 10.1515/CCLM.2010.138.

PMID:
20345231
8.

Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer.

Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW.

Clin Chem. 2002 Aug;48(8):1296-304.

9.

Investigation of early and advanced stages in ovarian cancer using human plasma by differential scanning calorimetry and mass spectrometry.

Kim NA, Jin JH, Kim KH, Lim DG, Cheong H, Kim YH, Ju W, Kim SC, Jeong SH.

Arch Pharm Res. 2016 May;39(5):668-76. doi: 10.1007/s12272-016-0722-z. Epub 2016 Mar 22.

PMID:
27002828
10.

Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients.

Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ, Feliberti EC, Perry RR, Drake RR.

J Am Coll Surg. 2009 May;208(5):970-8; discussion 978-80. doi: 10.1016/j.jamcollsurg.2008.12.024. Epub 2009 Mar 26.

PMID:
19476873
12.

Identification of novel serum peptides biomarkers for female breast cancer patients in Western China.

Yang J, Xiong X, Liu S, Zhu J, Luo M, Liu L, Zhao L, Qin Y, Song T, Huang C.

Proteomics. 2016 Mar;16(6):925-34. doi: 10.1002/pmic.201500321. Epub 2016 Feb 29.

PMID:
26705257
13.

Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples.

Freed GL, Cazares LH, Fichandler CE, Fuller TW, Sawyer CA, Stack BC Jr, Schraff S, Semmes OJ, Wadsworth JT, Drake RR.

Laryngoscope. 2008 Jan;118(1):61-8.

PMID:
18043497
14.

Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer.

Chung L, Moore K, Phillips L, Boyle FM, Marsh DJ, Baxter RC.

Breast Cancer Res. 2014 Jun 16;16(3):R63. doi: 10.1186/bcr3676.

15.

Construction of a multiple myeloma diagnostic model by magnetic bead-based MALDI-TOF mass spectrometry of serum and pattern recognition software.

Wang QT, Li YZ, Liang YF, Hu CJ, Zhai YH, Zhao GF, Zhang J, Li N, Ni AP, Chen WM, Xu Y.

Anat Rec (Hoboken). 2009 Apr;292(4):604-10. doi: 10.1002/ar.20871.

16.

Improved classification of breast cancer peptide and protein profiles by combining two serum workup procedures.

Velstra B, van der Burgt YE, Mertens BJ, Mesker WE, Deelder AM, Tollenaar RA.

J Cancer Res Clin Oncol. 2012 Dec;138(12):1983-92. doi: 10.1007/s00432-012-1273-4. Epub 2012 Jul 5.

17.

Serum peptidome patterns of breast cancer based on magnetic bead separation and mass spectrometry analysis.

Fan NJ, Gao CF, Zhao G, Wang XL, Liu QY.

Diagn Pathol. 2012 Apr 20;7:45. doi: 10.1186/1746-1596-7-45.

18.

Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry.

Shevchenko VE, Arnotskaya NE, Zaridze DG.

Eur J Mass Spectrom (Chichester). 2010;16(4):539-49. doi: 10.1255/ejms.1080.

PMID:
20625202
19.

Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling.

Gast MC, van Dulken EJ, van Loenen TK, Kingma-Vegter F, Westerga J, Flohil CC, Knol JC, Jimenez CR, van Gils CH, Wessels LF, Schellens JH, Beijnen JH.

Int J Biol Markers. 2009 Jul-Sep;24(3):130-41.

PMID:
19787623
20.

The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.

Hortin GL.

Clin Chem. 2006 Jul;52(7):1223-37. Epub 2006 Apr 27. Review.

Supplemental Content

Support Center